Despite advances in science and technology, denovo drug development has been a costly and time-consuming process over the past
decades. Given these circumstances, drug repositioning and repurposing has appeared as an alternative tool to accelerate drug development processes by seeking new indications for approved/shelved drugs rather than discovering de novo drug compounds.
The newest computational approach to drug repositioning showing the greatest promise is AI and machine learning. With a drug- repurposing strategy, AI can quickly detect drugs that can fight against emerging diseases (such as Covid-19) as well as existing diseases.
The AI Driven Drug Repositioning and Repurposing Summit will bring together 80+ leaders in repurposing and pioneers in AI and machine learning to strategize how repurposing can reach its full potential to:
- Improve time and cost savings of drug development
- Leverage the safety advantage in reducing development risk
- Unlock market potential advantage
- Improve return on investment for repurposed drugs
- Explore out-licensing options
This meeting aims to help pharma, biotech and academics stay ahead of the curve in their repurposing endeavors during a period exploding
with new technologies. Join cutting-edge discussions with the like of AstraZeneca, BenevolentAI, and Healx, to solve ongoing technical challenges surrounding AI tools in repurposing, understand the delicate risk-reward balance in potential repurposing opportunities and explore lessons learned from AI applications in repurposing during Covid-19.
Featuring 2 days of jam-packed content, this digital summit will provide you with all the information you need to begin implementing AI tools into repurposing projects within your organization. What's more, our digital platform allows you to take part in live Q and A with the presenters, take a tour of the virtual exhibition, and even join online rooms where you can join targeted interactive discussion groups!
Drug Developer - 2-Day Conference: USD 1999.0,
Academic - 2-Day Conference: USD 1799.0,
Solution Provider - 2-Day Conference: USD 2499.0
Speakers: David Hayes, Director, Emergent Innovations, AstraZeneca, Deepak Rajpal, Head, Translational Sciences, US, Sanofi, Ian Roberts, Director of Therapeutic Technology, Healx, Katherine Matsumoto, Director, Product Management, Recursion Pharma, Laura Kleiman, Founder and CEO, RebootRx, Peter Richardson, Vice President Pharmacology, BenevolentAI, Clare Thibodeaux, Director of Scientific Affairs, Cures Within Reach, Georgios Gerogiokas, Data Scientist, AstraZeneca, Kevin McLaren, Patent Attorney, Brannon Sowers and Cracraft PC, Pankaj Agarwal, Founder and CEO, BioInf, Sean Ekins, CEO, Collaborations Pharma, Steve Smith, Principal Computational Biology Data Scientist, Teva Pharmaceuticals, Angelo Pugliese, Team Lead, Computational Chemistry - Artificial Intelligence, Cancer Research UK Drug Discovery Unit, Aris Persidis, President, Biovista, Barbara Goodman, President and CEO, Cures Within Reach, Megan Golden, Co-Founder, Mission Cure, Rajiv Govindaraj, Senior Scientist, Computational Chemist, HotSpot Therapeutics, Sudeep Pushpakom, Lecturer in Pharmacology, University of Liverpool
Time: 08:30 - 17:30